Does Rallies show Form 4 insider transactions for ARQT?

Yes. Rallies tracks ARQT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ARQT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ARQT. It does not provide personalized investment advice.

ARQT (Arcutis Biotherapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Arcutis Biotherapeutics, Inc. Common Stock (ARQT) is a publicly traded Healthcare sector company. As of May 21, 2026, ARQT trades at $20.47 with a market cap of $2.51B and a P/E ratio of -676.83. ARQT moved +5.00% today. Year to date, ARQT is -32.22%; over the trailing twelve months it is +41.08%. Its 52-week range spans $8.03 to $31.77. Analyst consensus is strong buy with an average price target of $34.63. Rallies surfaces ARQT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ARQT stock inside the company?

Recent ARQT insider activity includes Vairavan Latha sold 435, Burnett Patrick sold 222, Matsuda Masaru sold 7.37K, Matsuda Masaru sold 884, and Burnett Patrick sold 684. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ARQT Key Metrics

Key financial metrics for ARQT
Metric	Value
Price	$20.47
Market Cap	$2.51B
P/E Ratio	-676.83
EPS	$-0.03
Dividend Yield	0.00%
52-Week High	$31.77
52-Week Low	$8.03
Volume	1.45K
Avg Volume	0
Revenue (TTM)	$415.62M
Net Income	$-2.38M
Gross Margin	90.94%

Recent ARQT Insider Trades

Vairavan Latha sold 435 (~$9.16K) on May 11, 2026.
Burnett Patrick sold 222 (~$4.67K) on May 11, 2026.
Matsuda Masaru sold 7.37K (~$171.54K) on May 4, 2026.
Matsuda Masaru sold 884 (~$20.87K) on May 4, 2026.
Burnett Patrick sold 684 (~$16.15K) on May 4, 2026.

Latest ARQT News

Arcutis ZORYVE Sales Reach $105.4M in Q1 with Infant sNDA Submission — May 6, 2026
Arcutis ZORYVE cream clears 49% of infants’ eczema by Week 4 — Mar 28, 2026
Arcutis to Unveil Late-Breaking Phase 2 Infant ZORYVE 0.05% Data at AAD — Mar 18, 2026
ZORYVE Cream 56-Week Study Shows 63% Clearance in 2–5 Year-Olds — Mar 10, 2026
Arcutis Elevates Mas Matsuda to EVP and Chief Legal Officer Overseeing ZORYVE Growth — Mar 5, 2026

ARQT Analyst Consensus

8 analysts cover ARQT: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $34.63.

Common questions about ARQT

Who is trading ARQT stock inside the company?: Recent ARQT insider activity includes Vairavan Latha sold 435, Burnett Patrick sold 222, Matsuda Masaru sold 7.37K, Matsuda Masaru sold 884, and Burnett Patrick sold 684. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ARQT?: Yes. Rallies tracks ARQT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ARQT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ARQT. It does not provide personalized investment advice.